IBM CEO: Watson Health is ‘Our Moonshot’ in Healthcare
By Greg Slabodkin,
Health Data Management
| 04. 20. 2015
Untitled Document
A new IBM business unit launched last week to help physicians, researchers, insurers and patients use big data, analytics and mobile technology to achieve better health outcomes is being described by the company’s chief executive officer as their “moonshot” in healthcare.
“If you go back in time, we have participated in some of the most glorious moments of history, whether it might have been the first systems that ever did census and landing a man on the moon,” said Ginni Rometty, chairman and CEO of IBM, on PBS’s Charlie Rose talk show. “I’m telling you our moonshot will be the impact we will have on healthcare. It has already started. We will do our part to change the face of healthcare. I am absolutely positive about it.”
Last week, IBM announced a new business unit—Watson Health—that will offer cloud-based access to its Watson supercomputer for analyzing healthcare data. Big Blue has partnered with Apple, Johnson & Johnson and Medtronic to make it easier for healthcare organizations to store and analyze patient data by leveraging Watson’s cognitive capabilities and...
Related Articles
By Emily Mullin, Wired | 04.23.2026
A STARTUP OUT of Utah, Paterna Biosciences, says it has successfully grown functional human sperm in a lab and used the sperm to make visibly healthy-looking embryos. The technique could eventually help men with certain types of infertility have biological children...
By Julianna LeMieux, Genetic Engineering & Biotechnology News | 04.14.2026
Twenty years ago, Sven Bocklandt, PhD, sought to create a hypoallergenic cat. He had the genetic engineering chops to do it, but the embryology was beyond his capabilities. At a small animal genetic engineering conference, known as TARC (Transgenic Animal...
By Laura DeFrancesco, Nature Biotechnology | 03.17.2026
The first gene editors designed to fix genetic lesions in mutation-agnostic ways are poised to enter the clinic. Tessera Therapeutics and Alltrna, two Flagship Pioneering-funded companies, are gearing up to test novel genetic medicines in humans. Tessera received regulatory clearance...
By Darren Incorvaia, Fierce Biotech | 03.11.2026
A new method for safely inserting large chunks of DNA into genomes has now measured up in mice, potentially paving the way for the next generation of gene editing medicines.
The approach, which is described in a Nature paper...